Subtopic Deep Dive

Nasal Drug Delivery Systems for Proteins and Peptides
Research Guide

What is Nasal Drug Delivery Systems for Proteins and Peptides?

Nasal drug delivery systems for proteins and peptides use permeation enhancers, nanoparticles, and mucoadhesive polymers to enable non-invasive transport of large biomolecules across the nasal epithelium for systemic absorption.

These systems address poor nasal bioavailability of macromolecules exceeding 1 kDa by employing chitosan nanoparticles and cyclodextrins as absorption promoters (Mohammed et al., 2017; Challa et al., 2005). Research focuses on formulations for insulin, vaccines, and hormones, with over 10,000 papers on nasal delivery since 2000. Key mechanisms include paracellular transport enhancement and enzymatic inhibition.

Curated Papers

Key Challenges

Why It Matters

Nasal delivery provides needle-free systemic access for protein therapeutics like insulin in diabetes management, bypassing hepatic first-pass metabolism (Mitchell et al., 2020). Chitosan nanoparticles improve peptide absorption for neurological disorders via olfactory pathways (Mohammed et al., 2017; Patra et al., 2018). Cyclodextrins stabilize peptides against nasal degradation, enabling vaccines and hormone therapies (Challa et al., 2005). This expands treatments for chronic conditions affecting millions, with nanoparticles achieving 2-5 fold bioavailability gains (Mohanraj and Chen, 2007).

Key Research Challenges

Low Biomolecule Permeability

Proteins and peptides face epithelial barriers and enzymatic degradation in nasal mucosa, limiting bioavailability below 1-2% (Mitchell et al., 2020). Nanoparticles like chitosan enhance paracellular transport but require optimization (Mohammed et al., 2017).

Mucociliary Clearance

Rapid nasal clearance reduces residence time to minutes, hindering absorption (Patra et al., 2018). Mucoadhesive agents like chitosan extend contact but risk irritation (Cheung et al., 2015).

Immunogenicity Risks

Nanoparticle adjuvants trigger immune responses, complicating vaccine delivery (Chenthamara et al., 2019). Balancing efficacy and safety remains unresolved (Mohanraj and Chen, 2007).

Essential Papers

Engineering precision nanoparticles for drug delivery

Michael J. Mitchell, Margaret M. Billingsley, Rebecca M. Haley et al. · 2020 · Nature Reviews Drug Discovery · 6.7K citations

Nano based drug delivery systems: recent developments and future prospects

Jayanta Kumar Patra, Gitishree Das, Leonardo Fernandes Fraceto et al. · 2018 · Journal of Nanobiotechnology · 6.2K citations

Controlled Drug Delivery Systems: Current Status and Future Directions

Shivakalyani Adepu, Seeram Ramakrishna · 2021 · Molecules · 1.4K citations

The drug delivery system enables the release of the active pharmaceutical ingredient to achieve a desired therapeutic response. Conventional drug delivery systems (tablets, capsules, syrups, ointme...

An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery

Munawar Mohammed, Jaweria Syeda, Kishor M. Wasan et al. · 2017 · Pharmaceutics · 1.3K citations

The focus of this review is to provide an overview of the chitosan based nanoparticles for various non-parenteral applications and also to put a spotlight on current research including sustained re...

Chitosan: An Update on Potential Biomedical and Pharmaceutical Applications

Randy Chi Fai Cheung, Tzi Bun Ng, Jack Ho Wong et al. · 2015 · Marine Drugs · 1.2K citations

Chitosan is a natural polycationic linear polysaccharide derived from chitin. The low solubility of chitosan in neutral and alkaline solution limits its application. Nevertheless, chemical modifica...

Cyclodextrins in drug delivery: An updated review

Rajeswari Challa, Alka Ahuja, Javed Ali et al. · 2005 · AAPS PharmSciTech · 1.2K citations

Nanoparticles - A review

Vellore J. Mohanraj, Y Chen · 2007 · Tropical Journal of Pharmaceutical Research · 1.2K citations

For the past few decades, there has been a considerable research interest in the area of drug delivery using particulate delivery systems as carriers for small and large molecules. Particulate syst...

Reading Guide

Foundational Papers

Start with Challa et al. (2005) for cyclodextrin mechanisms in delivery; Mohanraj and Chen (2007) for nanoparticle basics in biomolecule transport; Marques et al. (2011) for simulated nasal fluids testing.

Recent Advances

Mitchell et al. (2020) details precision nanoparticles for proteins; Mohammed et al. (2017) covers chitosan applications; Adepu and Ramakrishna (2021) reviews controlled release status.

Core Methods

Core techniques: chitosan nanoparticle formulation for mucoadhesion, cyclodextrin inclusion complexes for stability, simulated biological fluids for in vitro dissolution, paracellular enhancer screening via TEER measurements.

How PapersFlow Helps You Research Nasal Drug Delivery Systems for Proteins and Peptides

Discover & Search

Research Agent uses searchPapers for 'nasal chitosan nanoparticles peptides' yielding 500+ papers, then citationGraph on Mitchell et al. (2020) reveals 6743 citing works including nasal applications, and findSimilarPapers uncovers Mohammed et al. (2017) on chitosan for non-parenteral delivery.

Analyze & Verify

Analysis Agent applies readPaperContent to extract permeation data from Patra et al. (2018), verifies absorption claims via verifyResponse (CoVe) against simulated fluids in Marques et al. (2011), and runPythonAnalysis plots bioavailability curves from extracted datasets using matplotlib for statistical validation with GRADE scoring on evidence strength.

Synthesize & Write

Synthesis Agent detects gaps in immunogenicity studies across chitosan papers, flags contradictions in enhancer efficacy; Writing Agent uses latexEditText for formulation tables, latexSyncCitations for 20+ references, latexCompile for PDF, and exportMermaid for nasal transport pathway diagrams.

Use Cases

"Analyze peptide bioavailability data from nasal nanoparticle studies"

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas aggregation of absorption rates from 5 papers) → matplotlib plot of mean bioavailability vs. enhancer type.

"Draft LaTeX review on chitosan nasal delivery for insulin"

Synthesis Agent → gap detection → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (10 papers) → latexCompile → formatted PDF with nasal epithelium figure.

"Find code for simulating nasal drug absorption models"

Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python scripts for PK modeling from Mohanraj and Chen (2007) citations.

Automated Workflows

Deep Research workflow scans 50+ papers on nasal nanoparticles via searchPapers → citationGraph → structured report on enhancers (DeepScan adds 7-step verification with CoVe checkpoints on bioavailability claims). Theorizer generates hypotheses on peptide-nanoshell designs from Mitchell et al. (2020) and Mohammed et al. (2017), chaining gap detection to simulation prompts.

Try Doxa for Nasal Drug Delivery Systems for Proteins and Peptides Research

Frequently Asked Questions

What defines nasal drug delivery for proteins and peptides?

Formulations with nanoparticles, chitosan, and cyclodextrins enhance paracellular transport and inhibit enzymes for macromolecules >1 kDa across nasal epithelium (Mohammed et al., 2017; Challa et al., 2005).

What methods improve nasal peptide absorption?

Chitosan nanoparticles provide mucoadhesion and permeation via tight junction modulation; cyclodextrins complex peptides for stability (Patra et al., 2018; Cheung et al., 2015).

What are key papers on this topic?

Mitchell et al. (2020, 6743 citations) on precision nanoparticles; Mohammed et al. (2017, 1295 citations) on chitosan non-parenteral delivery; Challa et al. (2005, 1188 citations) on cyclodextrins.

What open problems exist?

Optimizing long-term safety of enhancers, scaling nasal vaccines without immunogenicity, and modeling variable mucociliary clearance (Chenthamara et al., 2019; Marques et al., 2011).